Kornimate/medical-research-clean huggingface dataset:
evaluating short-term effects of computerized brain fitness exercises in adult cochlear implant and/or hearing aid users

Conditions: Deafness; Speech Intelligibility

Summary: in this study we are testing computer-based brain fitness exercises. the games are designed to improve people's cognitive abilities brain functions, like memory, concentration, and ability to do two things at once. we are testing whether this cognitive training brain exercises will improve understanding of spoken sentences speech comprehension in people who use cochlear implant and/or hearing aids. we predict that cognitive training will improve speech comprehension in cochlear implant and/or hearing aid users.

aural rehabilitation is a life long process in spite of advanced innovative implant technology. existing standard therapy is inadequate for some people, because even after years of surgery many implant users does not obtain significant benefits, like improved understanding of spoken sentences. in many cases it seems that the speech comprehension deficits are linked to particular cognitive functions in cochlear implant users, including memory and attention. in this study we will test whether a computer-based set of "cognitive fitness" or "brain training" games designed to improve memory and attention will help cochlear implant and hearing aid users to understand speech better. cochlear implant and hearing aid users will complete 10 weeks of computer-based cognitive training on their home computers. half of participants will do this training immediately after being enrolled in the study; the other half will receive the training beginning 10 weeks after they are enrolled. speech comprehension and cognitive abilities will be assessed at baseline, 10, 20 and 30 weeks in all participants.

Eligibility criteria:
inclusion criteria: * adult cochlear implant users, and/or people with moderate/severe hearing loss using bilateral hearing aids, aged 19 or above * access to an internet-connect device that supports flash, and basic computer skills * medically stable patients exclusion criteria: * patients with epilepsy, severe visual and cognitive difficulties, chronic fatigue syndrome, and serious co-morbid conditions which could be exacerbated by the computer training games will be excluded for safety reasons. * patients who are unlikely to adhere to the intervention due to dementia, parkinson's disease, parkinson-plus syndrome, movement disorders or disability that would impair the person's ability to perform the training (e.g., problems with attention, alertness, or learning disorders) * participants who cannot speak english (since study materials are only in english), or unable to give consent.

Keywords: cochlear implants speech comprehension cognitive training cognitive fitness intervention memory attention rehabilitation
an emergency department-to-home intervention to improve quality of life and reduce hospital use

Conditions: ED Patients With Chronic Medical Illnesses

Summary: the purpose of this study is to determine if assigning older, chronically ill patients a healthcare coach after they leave the emergency department (ed) improves their quality of life and reduces the need for hospital-based care.

investigators will review the ed electronic medical record in real-time to determine ed patients' study eligibility. older, chronically ill ed patients who are eligible and agree to participate in the study will be randomly assigned to a healthcare coach and care transition intervention or usual, post-ed care. at the time of enrollment, all subjects will be asked to provide informed consent for study investigators to request medicare claims to determine how many ed visits, hospital admissions and doctor office visits the subject had at least 30 days after the index ed visit. all research participants will be asked basic personal information such as age, race, sex, employment and marital status. all subjects will be asked to complete a baseline survey about their quality of life. if the subject is assigned to the care transition intervention, the healthcare coach will visit the subject at home within 3 days of the ed visit. the coach will talk with the subject about following up with a regular, personal doctor and symptoms that indicate a worsening health condition. the coach will help the subject understand their medicines and help the subject make a personal health record (phr). the coach will tell the subject about the area agency on aging. if the subject receives usual care, they but will be given the usual discharge instructions from the ed nurse and doctor. if the subject receives the care transition intervention, the coach will also call the subject at least 3 times after the ed visit and review the same items listed above. all enrolled subjects will be asked to complete a phone survey within 31-60 days of the ed visit. this survey will again ask subjects about their quality of life.

Eligibility criteria:
inclusion criteria: * 60 years of age or older * medicare beneficiaries * community dwelling * reside within defined geographical area (to enable home visits) * have a working telephone * have at least one of the following conditions documented in their electronic medical record: congestive heart failure, chronic obstructive pulmonary disease, coronary artery disease, diabetes, stroke, pneumonia, medical and surgical back conditions (predominantly spinal stenosis), hip fracture, peripheral vascular disease, cardiac arrhythmias, deep venous thrombosis, pulmonary embolism, peptic ulcer disease or hemorrhage exclusion criteria: * current diagnosis of psychosis * cancer * dialysis * history of organ transplantation * dementia without a live-in caregiver, or * in hospice care * reside outside the defined geographical area * reside in a skilled nursing or assisted living facility

Keywords: healthcare coach care transition intervention emergency department population access to care
assessment of safety and efficacy of su11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.

Conditions: Colorectal Neoplasms

Summary: assessment of safety and efficacy of su11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.


Eligibility criteria:
inclusion criteria: * metastatic colorectal cancer * failed selected cancer therapies in the past. exclusion criteria: * prior treatment with tyrosine kinase inhibitors or vegf inhibitors other than bevacizumab.
the effects of tdcs combined with rtms on post-stroke cognitive impairment

Conditions: Stroke

Summary: if there is a comparison group: researchers will compare \[insert groups\] to see if \[insert effects\] the purpose of the clinical trial is to find a treatment for stroke patients with cognitive impairment, and the main questions it aims to answer are: * \[search for effective treatments of cognitive impairment after stroke\] * \[explore brain network features with functional near-infrared spectroscopy\] participants will receive conventional treatment, tdcs treatment, or rtms treatment, or tdcs-rtms treatment. and then compare cognitive function and brain function.


Eligibility criteria:
inclusion criteria: * meet the clinical diagnostic criteria of the expert consensus on the management of cognitive impairment after stroke in 2021; * 30-80 years old, right-handed, unilateral hemiplegia; * verbal expression can cooperate with the completion of the evaluation, sustained attention time is longer than 5 minutes; * simple mental state examination scale (mmse) score ≤26 points; moca scale score \< 26 points; memory test (rmbt) score less than 21 points; * patients or their family agree to sign the informed consent; * the ethics committee approved the trial. exclusion criteria: * memory dysfunction caused by other diseases, such as alzheimer's disease, lewy body dementia, pituitary tumor surgery, hypothyroidism, etc.; * there are contraindications of rtms and tdcs for untreated intracranial aneurysms, severe epilepsy, intracranial metal, etc. * patients with severe visual, cognitive or speech impairment who cannot cooperate with treatment; * the condition is not stable; or other serious physical diseases.
efficacy and safety of sacubitril/valsartan in african american patients with heart failure with reduced ejection fraction

Conditions: Heart Failure

Summary: there is limited long-term evidence specific to aas with hfref on sacubitril/valsartan therapy. plasma nt-probnp levels are lower in aa individuals as compared to caucasian individuals in general. however, the mechanism of action of sacubitril specifically targets the activity of bnp. therefore, there is the potential that the mechanism of action of sacubitril/valsartan may be less effective in aas.

to assess the efficacy and safety of sacubitril/valsartan in aa patients with hfref by comparing the outcomes of aa patients on arni therapy plus soc (with or without hydralazine/isosorbide \[h-idsn\]) to aa patients receiving acei/arb therapy plus soc (with or without h-isdn).

Eligibility criteria:
inclusion criteria: * self-identified as aa * nyha class ii-iv symptoms * left ventricle ef \<40% * receiving stable doses of standard therapy, including ace inhibitors or arbs, arni (within a month from discharge), combination h-isdn, beta blockers, digoxin, spironolactone, and diuretics as tolerated. * patient must have minimum of three months follow-up exclusion criteria: * patients not meeting inclusion criteria
a study of brodalumab (siliq®) in psoriasis participants with inadequate response to their current biologic agent regimen

Conditions: Psoriasis

Summary: this multicenter, prospective, observational, single-arm, 26-week study will evaluate the effectiveness, safety and tolerability of brodalumab subcutaneous injection in participants with psoriasis with inadequate response to their current biologic agent regimen.


Eligibility criteria:
inclusion criteria: * participant has enrolled in the brodalumab patient support program (psp). * participant has provided informed consent, using an independent ethics committee (iec) or institutional review board (irb) approved informed consent form (icf). * confirmed diagnosis with moderate to severe plaque psoriasis. * on stable treatment with a biologic for a minimum of 12 weeks, and not having achieved adequate therapeutic response, as per the investigator's judgment, for example bsa of greater than or equal to (≥) 1% and physicians global assessment (pga) of ≥3. * participant must be able to understand and communicate with the investigator, as well as complete the study questionnaires, in one of the available and validated languages. * participants participating in other observational studies or registries are permitted to enroll in this study at the same time. exclusion criteria: * receiving or has received any investigational drug (or is currently using an investigational device) within 30 days or 5 drug half-lives (whichever is longer) prior to receiving the first dose of brodalumab (day 1). * participant has a history of any psychiatric disorder or substance abuse that, in the opinion of the investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. * participant has previous history of suicidal ideation and/or behavior or report suicidal ideation and/or behavior during the study. * presence of any other serious and/or uncontrolled medical condition that, in the opinion of the investigator, prohibits the participant from participating in the study. * participant has a body mass index (bmi) greater than (\>) 40 kilograms/square meter (kg/m\^2) during the screening phase or during the study. * any contraindication as per the product monograph: brodalumab injection is contraindicated in participants with clinically significant hypersensitivity to brodalumab or to any of the excipients or component of the container. brodalumab is contraindicated in participants with crohn's disease.
efficacy and safety of grt6005 in patients with chronic low back pain.

Conditions: Low Back Pain

Summary: the purpose of this trial is to evaluate the safety and efficacy of once daily orally administered grt6005 in a total of 3 fixed doses compared to placebo in subjects with moderate to severe chronic low back pain (lbp). the study includes a maximum of 21 days screening period followed by a 2-week titration period and 12-week maintenance double-blind treatment period and a 10-14 day safety follow up period. patients who are eligible for the double-blind treatment period will be randomized to one of the following treatment groups: grt6005 low-dose, grt6005 medium dose, grt6005 high-dose, tapentadol or placebo.


Eligibility criteria:
inclusion criteria: * chronic low back pain of non-malignant origin and present for at least 3 months. * signed informed consent. * pain intensity score of 5 or greater on the 11-point numeric rating scale (where 0 indicates "no pain" and 10 indicates "as bad as you can imagine"). * on stable analgesic medications (non-opioid and/or opioid medications) for chronic low back pain with regular intake for at least 3 months and dissatisfied with current analgesic treatment. exclusion criteria: * female subjects who are pregnant or are breastfeeding. * presence of risk factors for torsade de pointes. * any clinically significant disease or laboratory findings that may affect efficacy or safety assessments or may compromise the safety during trial participation, e.g., significant unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, metabolic, neurological, or psychiatric disorders. * history of acute hepatitis within the past 3 months or chronic hepatitis or a positive result on anti-hepatitis a antibody, hepatitis b surface antigen, or anti-hepatitis c antibody. history of human immunodeficiency virus (hiv) infection. * history of seizure disorder. * chronic low back pain potentially associated with a specific spinal cause. * surgery or painful procedure during or within 3 months of enrollment. * conditions that contribute and confound the assessment of pain. * subjects with impaired renal function. * subjects with impaired hepatic functionality. * neuromodulation. * cancer. * clinically relevant history of hypersensitivity, allergy or contraindications to any of the investigational medicinal products' excipients, paracetamol/acetaminophen, tapentadol hydrochloride, or opioid analgesics (or excipients).
a dose ranging study comparing different combinations of adjuvanted and non-adjuvanted influenza vaccines in healthy children 6 to <36 months of age

Conditions: Influenza

Summary: this study will evaluate the safety and immunogenicity of different combinations of influenza vaccine in healthy young children.


Eligibility criteria:
inclusion criteria: * children of 6 month to \<36 month of age in good health as determined by medical history, physical assessment and clinical judgement of the investigator. exclusion criteria: * history of serious disease. history of serious reaction following administration of vaccine or hypersensitivity to vaccine components. known or suspected impairment/alteration of immune function.

Keywords: influenza flu vaccine adjuvant
spironolactone in covid-19 induced ards

Conditions: Respiratory Distress Syndrome, Adult

Summary: this study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ards patients.


Eligibility criteria:
inclusion criteria: * hemodynamically stable * hypoxemia, i.e. p/f \<150 * admitted to icu within 48 hours * not moribund has a life expectancy greater than 24 hours exclusion criteria: * age criteria * pregnancy * unwillingness to participate
comt polymorphism and entacapone efficacy

Conditions: Parkinson's Disease

Summary: entacapone is an antiparkinsonian drug which block l-dopa metabolism, inhibiting the c-o-methyltransferase (comt) enzyme. there is an individual variability of the comt activity determined by a genetic polymorphism. the aim of this study is to investigate whether the genetic variability influences entacapone efficacy in parkinson's disease.

comt protein is dependent of a single autosomal locus with two co-dominant alleles with a high activity (allele h) and a low activity (allele l) form of the enzyme. l and h allele frequency in the caucasian population is around 50%. this is a monocentric randomized blinded cross-over study comparing acute challenge of l-dopa + placebo versus l-dopa + 200 mg entacapone, in parkinson's disease patients with hh and ll genotypes.

Eligibility criteria:
inclusion criteria: * parkinson's disease * wearing off exclusion criteria: * atypical parkinsonism * neuroleptic use

Keywords: parkinson's disease catechol o-methyltransferase entacapone pharmacogenetic
role of herbs in the management of asthma

Conditions: Bronchial Asthma

Summary: the aim of this trial is to study the effect of a polyherbal capsule containing four herbs: inula racemosa, ocimum sanctum, terminalia belerica and piperum longum in the treatment of bronchial asthma.

a randomized placebo controlled double blind trial. four herbs that have proven efficacy on bronchial asthma will be given. equally matched placebo will be given randomly to patients. each arm active herbs and placebo will be compared against the formoterol+fluticasone single maintenance and reliever therapy(smart) and conventional therapy. all the parameters of bronchial asthma(ba) will be compared between the randomized groups.

Eligibility criteria:
inclusion criteria: * adults aged ≥ 18 years. * history of asthma documented by a physician for at least 6 months * patients on steroid therapy for at least 4 weeks. * if not on steroid therapy, patient and physician must be willing for 4 weeks run in on steroid therapy. * the subject agrees to participate in the study exclusion criteria: * any one of the following * acute illness (such as cold, flu, etc.) within one week before the administration of study drug * abnormal hepatic and renal function * pregnant, attempting to conceive, or lactating women * current or former employees of organic india * participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days. * physician uncomfortable with patient compliance to treatments or follow up. * non-compliance to tobacco cessation therapy.
a study of jnj-75276617 in combination with conventional chemotherapy for pediatric and young adult participants with relapsed/refractory acute leukemias

Conditions: Acute Leukemias; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Acute Leukemia of Ambiguous Lineage

Summary: the purpose of this study is to determine the recommended phase 2 dose(s) (rp2ds) of jnj-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute leukemia harboring histone-lysine n-methyltransferase 2a1 (\[kmt2a1\], nucleophosmin 1 gene (npm1), or nucleoporin alterations in part 1 (dose escalation) and to further evaluate safety at the rp2d(s) of jnj-75276617 in combination with chemotherapy in pediatric and young adult participants with relapsed/refractory acute leukemia harboring kmt2a1, npm1, or nucleoporin alterations and safety at the rp2d(s) of jnj-75276617 as monotherapy in a select low burden of disease cohort in part 2 (dose expansion).


Eligibility criteria:
inclusion criteria: * acute leukemia harboring histone-lysine n-methyltransferase 2a (kmt2a) or nucleophosmin 1 gene (npm1) or nucleoporin (nup98 or nup214) alterations * performance status greater than or equal to (\>=) 50 by lansky scale (for participants less than \[\ =50 percent (%) karnofsky scale (for participants \>=16 years of age) * estimated or measured glomerular filtration rate \>= 60 milliliter per minute per 1.73 meter square (ml/min/1.73m\^2) based on the bed side schwartz formula exclusion criteria: * received an allogeneic hematopoietic transplant within 60 days of screening * active acute graft-versus-host disease of any grade or chronic graft-versus-host which is not well-controlled * received immunosuppressive therapy post hematopoietic transplant within 30 days of enrollment * diagnosis of down syndrome associated leukemia, acute promyelocytic leukemia, juvenile myelomonocytic leukemia * diagnosis of fanconi anemia, kostmann syndrome, shwachman diamond syndrome, or any other known bone marrow failure syndrome * prior exposure to menin-kmt2a inhibitors * prior cancer immunotherapy (ie \[that is\], chimeric antigen receptor-t cell therapy \[car-t\], inotuzumab, gemtuzumab ozogamicin) within 4 weeks prior to enrollment or blinatumomab within 2 weeks prior to enrollment. additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)
bioclinical study of scalp photoaging of a population male over 65 years old.

Conditions: Skin Aging; Skin Cancer

Summary: the aging of skin, especially that of the scalp, is a combination of intrinsic and extrinsic aging factors secondary to the chronic sun exposure. for men with an alopecia genetic (= bald men), the solar part, in skin aging process, is major. the helio-dermal scalp is frequently the site of cancers mainly after 65 years. objectives are to identify specific biomarkers involved in the photo-aging of the alopecic scalp

investigators can also hope to understand and to explain the inter-individual inequality of the aging of skin. they can hope to a better understanding of the biological mechanisms between photo-induced skin aging and photo-induced carcinogenesis. investigators propose to study 40 male patients aged 65 and over in order to compare the state of aging of their scalp skin in the alopecic zone : not hairy photo-exposed (= zh sun damage zone) versus occipital hair zone protected photo (= zt control zone). patients will be recruited in the dermatology department of the st-etienne university hospital who will benefit from the removal of a scalp tumour in the alopecic zone. this study aims to identify biological markers, by transcriptomic analysis, associated with aging of the scalp, by comparing for each patient the skin of the scalp exposed to the light ("zh") to an unexposed witness skin ("zt"). the study will include : * examinations to characterize components of the scalp: transcriptomic, proteomic and immunohistochemical analysis of skin biopsies, and a swab sampling will identify the cutaneous microflora of the scalp * noninvasive examinations, in vivo

Eligibility criteria:
inclusion criteria: * requiring excision of an alopecic scalp lesion * from consent signed * patient affiliated or entitled to a social security. exclusion criteria: * scalp infection * inflammatory disease of the scalp * genetic disease with even partial expression of the scalp * medical treatment of scalp less than 3 weeks old * antecedent radiotherapy of the cephalic extremity * prior surgery of the scalp with regard to the area sampled * application of hair implants, or any other surgical or medical procedures of the scalp * washing of the scalp or application of a cosmetic product for less than 48 hours * artificial hair coloring. * any contraindication to surgical excision

Keywords: biologic markers skin cancer solar aging of skin alopecic scalp